Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1988 May;94(1):137–147. doi: 10.1111/j.1476-5381.1988.tb11508.x

Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors.

G A Kennett 1, G Curzon 1
PMCID: PMC1853919  PMID: 3401632

Abstract

1. The effects of 1-(3-chlorophenyl)piperazine (mCPP) and 1-[3-(trifluoromethyl)phenyl] piperazine (TFMPP) on activity of rats in a novel cage, and on the rotorod and elevated bar co-ordination tests was examined. 2. Peripherally administered mCPP and TFMPP dose-dependently reduced locomotion, rearing, and feeding scores but not grooming of freely fed rats placed in a novel observation cage. Yawning behaviour was increased. Similar effects were also observed after injection of mCPP into the 3rd ventricle. 3. Co-ordination on a rotating drum of both untrained and trained rats was impaired following mCPP but co-ordination on an elevated bar was not. 4. The hypoactivity induced by mCPP was opposed by three antagonists with high affinity for the 5-hydroxytryptamine (5-HT1C) site; metergoline, mianserin, cyproheptadine and possibly also by a fourth antagonist mesulergine. Metergoline, mianserin and cyproheptadine also opposed the reduction in feeding scores. However, neither effect of mCPP was antagonized by the 5-HT2-receptor antagonists ketanserin or ritanserin, the 5-HT3-receptor antagonist ICS 205-930, the 5-HT1A and 5-HT1B-receptor antagonists (-)-pindolol, (-)-propranolol and (+/-)-cyanopindolol or the 5-HT1A-, 5-HT2- and dopamine receptor antagonist spiperone. The specific alpha 2-adrenoceptor antagonist idazoxan was also without effect. 5. Hypoactivity induced by TFMPP was similarly antagonized by mianserin but unaffected by (+/-)-cyanopindolol. 6. These results suggest that the hypoactivity is mediated by central 5-HT1C-receptors and that mCPP and possibly TFMPP may be 5-HT1C-receptor agonists. 7. As mianserin, cyproheptadine and mesulergine in the absence of mCPP did not increase locomotion but increased the number of feeding scores, the activation of 5-HT1C-receptors may be of physiological importance in the control of appetite. The possible relevance of these results to the therapeutic and side-effects of clinically used antidepressants (particularly trazodone and mianserin) and anorexigenic drugs is discussed.

Full text

PDF
137

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aloi J. A., Insel T. R., Mueller E. A., Murphy D. L. Neuroendocrine and behavioral effects of m-chlorophenylpiperazine administration in rhesus monkeys. Life Sci. 1984 Apr 2;34(14):1325–1331. doi: 10.1016/0024-3205(84)90003-1. [DOI] [PubMed] [Google Scholar]
  2. Asarch K. B., Ransom R. W., Shih J. C. 5-HT-1a and 5-HT-1b selectivity of two phenylpiperazine derivatives: evidence for 5-HT-1b heterogeneity. Life Sci. 1985 Apr 1;36(13):1265–1273. doi: 10.1016/0024-3205(85)90271-1. [DOI] [PubMed] [Google Scholar]
  3. BERGEN S. S., Jr APPETITE STIMULATING PROPERTIES OF CYPROHEPTADINE. Am J Dis Child. 1964 Sep;108:270–273. doi: 10.1001/archpedi.1964.02090010272008. [DOI] [PubMed] [Google Scholar]
  4. Bedard P., Pycock C. J. "Wet-dog" shake behaviour in the rat: a possible quantitative model of central 5-hydroxytryptamine activity. Neuropharmacology. 1977 Oct;16(10):663–670. doi: 10.1016/0028-3908(77)90117-4. [DOI] [PubMed] [Google Scholar]
  5. Blundell J. E. Serotonin and appetite. Neuropharmacology. 1984 Dec;23(12B):1537–1551. doi: 10.1016/0028-3908(84)90098-4. [DOI] [PubMed] [Google Scholar]
  6. Blurton P. A., Wood M. D. Identification of multiple binding sites for [3H]5-hydroxytryptamine in the rat CNS. J Neurochem. 1986 May;46(5):1392–1398. doi: 10.1111/j.1471-4159.1986.tb01753.x. [DOI] [PubMed] [Google Scholar]
  7. Bradley P. B., Engel G., Feniuk W., Fozard J. R., Humphrey P. P., Middlemiss D. N., Mylecharane E. J., Richardson B. P., Saxena P. R. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology. 1986 Jun;25(6):563–576. doi: 10.1016/0028-3908(86)90207-8. [DOI] [PubMed] [Google Scholar]
  8. Caccia S., Fong M. H., Garattini S., Zanini M. G. Plasma concentrations of trazodone and 1-(3-chlorophenyl)piperazine in man after a single oral dose of trazodone. J Pharm Pharmacol. 1982 Sep;34(9):605–606. doi: 10.1111/j.2042-7158.1982.tb04807.x. [DOI] [PubMed] [Google Scholar]
  9. Clineschmidt B. V., Flataker L. M., Faison E., Holmes R. An in vivo model for investigating alpha 1- and alpha 2-receptors in the CNS: studies with mianserin. Arch Int Pharmacodyn Ther. 1979 Nov;242(1):59–76. [PubMed] [Google Scholar]
  10. Closse A. [3H]Mesulergine, a selective ligand for serotonin-2 receptors. Life Sci. 1983 May 23;32(21):2485–2495. doi: 10.1016/0024-3205(83)90375-2. [DOI] [PubMed] [Google Scholar]
  11. Engel G., Göthert M., Hoyer D., Schlicker E., Hillenbrand K. Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites. Naunyn Schmiedebergs Arch Pharmacol. 1986 Jan;332(1):1–7. doi: 10.1007/BF00633189. [DOI] [PubMed] [Google Scholar]
  12. Feighner J. P. Trazodone, a triazolopyridine derivative, in primary depressive disorder. J Clin Psychiatry. 1980 Jul;41(7):250–255. [PubMed] [Google Scholar]
  13. Heuring R. E., Peroutka S. J. Characterization of a novel 3H-5-hydroxytryptamine binding site subtype in bovine brain membranes. J Neurosci. 1987 Mar;7(3):894–903. doi: 10.1523/JNEUROSCI.07-03-00894.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hoyer D., Engel G., Kalkman H. O. Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[125I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin. Eur J Pharmacol. 1985 Nov 26;118(1-2):13–23. doi: 10.1016/0014-2999(85)90658-2. [DOI] [PubMed] [Google Scholar]
  15. Kennett G. A., Dourish C. T., Curzon G. 5-HT1B agonists induce anorexia at a postsynaptic site. Eur J Pharmacol. 1987 Sep 23;141(3):429–435. doi: 10.1016/0014-2999(87)90561-9. [DOI] [PubMed] [Google Scholar]
  16. Leysen J. E., Awouters F., Kennis L., Laduron P. M., Vandenberk J., Janssen P. A. Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci. 1981 Mar 2;28(9):1015–1022. doi: 10.1016/0024-3205(81)90747-5. [DOI] [PubMed] [Google Scholar]
  17. Leysen J. E., Gommeren W., Van Gompel P., Wynants J., Janssen P. F., Laduron P. M. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. Mol Pharmacol. 1985 Jun;27(6):600–611. [PubMed] [Google Scholar]
  18. Middlemiss D. N., Fozard J. R. 8-Hydroxy-2-(di-n-propylamino)-tetralin discriminates between subtypes of the 5-HT1 recognition site. Eur J Pharmacol. 1983 May 20;90(1):151–153. doi: 10.1016/0014-2999(83)90230-3. [DOI] [PubMed] [Google Scholar]
  19. Nickolson V. J., Wieringa J. H., van Delft A. M. Comparative pharmacology of mianserin, its main metabolites and 6-azamianserin. Naunyn Schmiedebergs Arch Pharmacol. 1982 Apr;319(1):48–55. doi: 10.1007/BF00491478. [DOI] [PubMed] [Google Scholar]
  20. Pazos A., Hoyer D., Palacios J. M. The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. Eur J Pharmacol. 1984 Nov 27;106(3):539–546. doi: 10.1016/0014-2999(84)90057-8. [DOI] [PubMed] [Google Scholar]
  21. Pazos A., Palacios J. M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res. 1985 Nov 4;346(2):205–230. doi: 10.1016/0006-8993(85)90856-x. [DOI] [PubMed] [Google Scholar]
  22. Pedigo N. W., Yamamura H. I., Nelson D. L. Discrimination of multiple [3H]5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain. J Neurochem. 1981 Jan;36(1):220–226. doi: 10.1111/j.1471-4159.1981.tb02397.x. [DOI] [PubMed] [Google Scholar]
  23. Peroutka S. J., Snyder S. H. Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol. 1979 Nov;16(3):687–699. [PubMed] [Google Scholar]
  24. Pinder R. M., Brogden R. N., Sawyer P. R., Speight T. M., Avery G. S. Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity. Drugs. 1975;10(4):241–323. doi: 10.2165/00003495-197510040-00001. [DOI] [PubMed] [Google Scholar]
  25. Richardson B. P., Engel G., Donatsch P., Stadler P. A. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature. 1985 Jul 11;316(6024):126–131. doi: 10.1038/316126a0. [DOI] [PubMed] [Google Scholar]
  26. Samanin R., Mennini T., Ferraris A., Bendotti C., Borsini F., Garattini S. Chlorophenylpiperazine: a central serotonin agonist causing powerful anorexia in rats. Naunyn Schmiedebergs Arch Pharmacol. 1979 Aug;308(2):159–163. doi: 10.1007/BF00499059. [DOI] [PubMed] [Google Scholar]
  27. Scatton B., Dedek J., Zivkovic B. Lack of involvement of alpha 2-adrenoceptors in the regulation of striatal dopaminergic transmission. Eur J Pharmacol. 1983 Jan 21;86(3-4):427–433. doi: 10.1016/0014-2999(83)90192-9. [DOI] [PubMed] [Google Scholar]
  28. Shearman G. T., Tolcsvai L. Effect of the selective 5-HT3 receptor antagonists ICS 205-930 and MDL 72222 on 5-HTP-induced head shaking and behavioral symptoms induced by 5-methoxy-N,N,dimethyltryptamine in rats: comparison with some other 5-HT receptor antagonists. Psychopharmacology (Berl) 1987;92(4):520–523. doi: 10.1007/BF00176488. [DOI] [PubMed] [Google Scholar]
  29. Sills M. A., Wolfe B. B., Frazer A. Determination of selective and nonselective compounds for the 5-HT 1A and 5-HT 1B receptor subtypes in rat frontal cortex. J Pharmacol Exp Ther. 1984 Dec;231(3):480–487. [PubMed] [Google Scholar]
  30. Smith T. M., Suckow R. F. Trazodone and m-chlorophenylpiperazine. Concentration in brain and receptor activity in regions in the brain associated with anxiety. Neuropharmacology. 1985 Nov;24(11):1067–1071. doi: 10.1016/0028-3908(85)90193-5. [DOI] [PubMed] [Google Scholar]
  31. Snyder S. H. Tricyclic antidepressant drug interactions with histamine and alpha-adrenergic receptors. Pharmakopsychiatr Neuropsychopharmakol. 1980 Mar;13(2):62–67. doi: 10.1055/s-2007-1019614. [DOI] [PubMed] [Google Scholar]
  32. Tricklebank M. D., Forler C., Fozard J. R. The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur J Pharmacol. 1984 Nov 13;106(2):271–282. doi: 10.1016/0014-2999(84)90714-3. [DOI] [PubMed] [Google Scholar]
  33. Tricklebank M. D., Middlemiss D. N., Neill J. Pharmacological analysis of the behavioural and thermoregulatory effects of the putative 5-HT1 receptor agonist, RU 24969, in the rat. Neuropharmacology. 1986 Aug;25(8):877–886. doi: 10.1016/0028-3908(86)90014-6. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES